TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02078622

Intervention type: OTHER
Intervention: Respiratory Therapist Education and Case Management
Description: Respiratory Therapists will conduct home care visits over a period of one-year at two-week intervals
Study: NCT01345786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Commercial NOMAC-E2
Description: 1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination commercial tablet orally in the morning on Day 1 for all periods
Study: NCT01102660

Intervention type: DRUG
Group type: OTHER
Intervention: PH-797804
Description: Tablet, 6 mg once daily for 2 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Naproxen
Description: Tablet, 500 mg twice daily for 2 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Naproxen + PH-797804
Description: Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Naproxen + PH-797804
Description: Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Naproxen
Description: Tablet, 500 mg twice daily for 2 weeks
Study: NCT03643744

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 14 placebo capsules taken 1 in the morning and 1 in the evening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 14 placebo capsules taken 1 in the morning and 1 in the evening.
Study: NCT00884390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moroctocog alfa (AF-CC) (ReFacto AF)
Description: Providing moroctocog alfa (AF-CC) as test article for use during this study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laboratory tests
Description: Laboratory samples are collected during study visits, in order to collect safety and efficacy data related to the administration of test article.
Study: NCT02050165

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KIND Bars
Description: Consumption of KIND Bars for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Typical American Snack
Description: Consumption of typical American snacks for 12 weeks
Study: NCT03102385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: A web-based computer-tailored intervention that includes open-ended questions, reflective responses, affirmations, and summarizing, as well as informing and advising. Specific topics include 1) individual motivations for giving, 2) the relationship between past donation behavior and the individual's personal goals/values, 3) donation importance and confidence rulers, 4) addressing donor concerns, and 5) summarizing.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Knowledge Interview
Description: A web-based interview that includes open-ended questions regarding blood donation knowledge.
Study: NCT00702507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25 % Miconazole Nitrate Ointment
Description: Topical Application
Study: NCT03755596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z. officinale extract
Description: Oral dose of 160mg dry ginger root (Z. officinale) extract in tablet form.
Study: NCT02571257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: 1-300 mg tablet, QD, 56 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: 3-300 mg tablets, QD, 56 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00564031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femanest
Description: 2mg/day
Study: NCT04114396

Intervention type: DRUG
Intervention: Anti-IL5 Antibody
Description: Asthma group: Anti-IL5 treatment Control group: No biologic.

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Optional for both arms

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Optional for both arms
Study: NCT02528955

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: A: De-Intensification RT primary tumor region
Description: A:~* Reduction of radiation dose in the primary tumor region to 56 Gy,~* Elective Radiotherapy of both neck sides

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: B: De-Intensification RT contralateral lymph nodes
Description: B:~* No dose reduction in primary tumor region (prescribed dose in primary tumor region: 64 Gy)~* Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no contralateral neck irradiation
Study: NCT01345786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Commercial NOMAC-E2
Description: 1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination commercial tablet orally in the morning on Day 1 for all periods

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phase 3 NOMAC-E2 Batch A
Description: 1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch A) orally in the morning on Day 1 for all periods
Study: NCT02528955

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: C. De-Intensification RT primary tumor region AND contralateral lymph nodes
Description: C:~* Reduction of radiation dose in the primary tumor region to 56 Gy, AND~* Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no contralateral neck irradiation
Study: NCT01345786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phase 3 NOMAC-E2 Batch B
Description: 1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch B) orally in the morning on Day 1 for all periods
Study: NCT01870609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: defactinib (VS-6063)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic defactinib tablet
Study: NCT02521064

Intervention type: DIETARY_SUPPLEMENT
Intervention: Exclusive Enteral Nutrition (EEN)
Description: Patients will be treated with 8 weeks of Exclusive Enteral Nutrition (EEN). Patients will continue to receive usual medical care, and concurrent IBD treatments will be permitted.

Intervention type: DRUG
Intervention: Prednisone
Description: Patients will be treated with 8 weeks of prednisone (corticosteroid). Patients will continue to receive usual medical care, and concurrent IBD treatments will be permitted.
Study: NCT02422043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires and audio-tape interviews
Description: therapeutic patient education programs (TPE) to type 1 diabetic adolescents are designed to make the teenager to self manage their disease and their treatment. Based on Bandura's social cognitive theory, effects of educational activities for TPE should lead to the strengthening of self-efficacy
Study: NCT03268746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof IQ PanOptix Multifocal IOL
Description: AcrySof IQ PanOptix Multifocal IOL Model TFNT00 for near, intermediate, and distance vision intended for long-term use over the lifetime of the cataract subject
Study: NCT05393583

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Outpatient hysterectomy
Description: Discharge on the day of the hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient hysterectomy
Description: 1 night hospital stay after hysterectomy
Study: NCT05518344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viziatek ISL™ (hereinafter referred to as the ISL) implanted in blind eye.
Description: Viziatek ISL™ (hereinafter referred to as the ISL) implanted in blind eye.
Study: NCT04495361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-learning portal
Description: An online learning portal for the identification and management of pneumonia in under five children
Study: NCT02140918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone 100 μg
Description: Fludrocortisone 100 μg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone 200 μg
Description: Fludrocortisone 200 μg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone 400 μg
Description: Fludrocortisone 400 μg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02219594

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CT image for patient with suspected in-stent restenosis
Description: Gemstone CT or 320-detector row spiral CT was assigned randomly to patient who was suspected in-stent restenosis.About after 10 days,they would accept the check of OCT which wold be the gold standard of in-stent restenosis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT image for patient with suspected in-stent restenosis
Description: Gemstone CT or 320-detector row spiral CT was assigned randomly to patient who was suspected in-stent restenosis.About after 10 days,they would accept the check of OCT which wold be the gold standard of in-stent restenosis.
Study: NCT03656016

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Phase contrast magnetic resonance imaging technique

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Phase contrast magnetic resonance imaging technique
Study: NCT02713997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: 50 mg on day 0 SQ; 25 mg subcutaneous (SQ) on days 3, 7, 10, 14, and 21 relative to TPIAT
Study: NCT00109733

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone
Description: 0.005 mg/kg/day for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.
Study: NCT02713997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha 1-Antitrypsin
Description: 90 mg/kg intravenous infusion on days -1, and +3, 7, 14, 21, and 28 post-transplant
Study: NCT03251378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib (HMPL-013)
Description: Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class.
Study: NCT02374086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Study: NCT03251378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib (HMPL-013)
Description: Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib (HMPL-013)
Description: Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib (HMPL-013)
Description: Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class.
Study: NCT03524079

Intervention type: DRUG
Intervention: Ajmaline 17-(Chloroacetate) Monohydrochloride
Description: Ajmaline 17-(Chloroacetate) Monohydrochloride(1mg/kg in 5 minutes)
Study: NCT00109733

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone
Description: 0.010 mg/kg/day for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.
Study: NCT01263535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish
Description: Contact lens-based device for the continuous recording of IOP fluctuations, with a portable recording system
Study: NCT04365816

Intervention type: OTHER
Intervention: Interview
Description: A survey was created, aiming to collect information about prior history of chronic disease, the Self-Evaluation of Food Intake, dysregulations (anosmia, ageusia...), anthropometric data, food data during and after hospitalisation, healthcare consumption since the discharge from hospital
Study: NCT03251378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib (HMPL-013)
Description: Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib (HMPL-013)
Description: Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class.
Study: NCT01090037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-100STP high dose
Study: NCT04365816

Intervention type: OTHER
Intervention: Interview
Description: A survey was created, aiming to collect information about prior history of chronic disease, the Self-Evaluation of Food Intake, dysregulations (anosmia, ageusia...), anthropometric data, food data during and after hospitalisation, healthcare consumption since the discharge from hospital

Intervention type: OTHER
Intervention: Interview
Description: A survey was created, aiming to collect information about prior history of chronic disease, the Self-Evaluation of Food Intake, dysregulations (anosmia, ageusia...), anthropometric data, food data during and after hospitalisation, healthcare consumption since the discharge from hospital

Intervention type: OTHER
Intervention: Interview
Description: A survey was created, aiming to collect information about prior history of chronic disease, the Self-Evaluation of Food Intake, dysregulations (anosmia, ageusia...), anthropometric data, food data during and after hospitalisation, healthcare consumption since the discharge from hospital

Intervention type: OTHER
Intervention: Interview
Description: A survey was created, aiming to collect information about prior history of chronic disease, the Self-Evaluation of Food Intake, dysregulations (anosmia, ageusia...), anthropometric data, food data during and after hospitalisation, healthcare consumption since the discharge from hospital

Intervention type: OTHER
Intervention: Interview
Description: A survey was created, aiming to collect information about prior history of chronic disease, the Self-Evaluation of Food Intake, dysregulations (anosmia, ageusia...), anthropometric data, food data during and after hospitalisation, healthcare consumption since the discharge from hospital

Intervention type: OTHER
Intervention: Interview
Description: A survey was created, aiming to collect information about prior history of chronic disease, the Self-Evaluation of Food Intake, dysregulations (anosmia, ageusia...), anthropometric data, food data during and after hospitalisation, healthcare consumption since the discharge from hospital
Study: NCT03339648

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Professional Development Enhancement
Description: Professional development for SROs enhanced by content concerning trauma-informed care, cultural competency, restorative justice, and social-emotional learning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional Development Enhancement
Description: Professional development for SROs enhanced by content concerning trauma-informed care, cultural competency, restorative justice, and social-emotional learning.
Study: NCT04014153

Intervention type: PROCEDURE
Intervention: Iodinated contrast media
Description: Percutaneous coronary intervention with iodinated contest media

Intervention type: PROCEDURE
Intervention: Iodinated contrast media
Description: Percutaneous coronary intervention with iodinated contest media
Study: NCT06326840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: All participants were administered 1500 mg/day of metformin for eight weeks. The trial design is single-group with no masking.
Study: NCT01591018

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sonolysis
Description: continual transcranial Doppler monitoring with max. diagnostic intensity for min. 60 minutes
Study: NCT01806727

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Lifestyle Weight Loss (LWL)
Description: Changing dietary and physical activity behavior to promote weight loss
Study: NCT00564031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gestapuran
Description: 5mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femanest plus Gestapuran
Description: combined daily
Study: NCT04392596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone Mineral Density and Trabecular Bone score
Description: structural damage in the cervical and lumbar spine was scored according to the modified Stoke AS Spinal Score (mSASSS) which yielded a final summation score ranging from zero to 72.~BMD was measured using DXA (Lunar Prodigy densitometer, GE Healthcare, Madison, WI, USA).~BMD was measured at the lumbar spine (L1-L4) and the left hip (femoral neck and total proximal femur).~TBS was analyzed using DXA images over exactly the same region as the lumbar BMD assessment (L1-L4). Lumbar spine DXA images were reanalyzed using TBS iNight software version 2.1 (Med-I maps, Merignac, France). Patients were divided in 3 TBS groups according to guidelines for fracture risk \[22\]: any TBS \>1.31 was considered as normal; TBS values between 1.23 and 1.31 were consistent as partially degraded structure; and any TBS \<1.23 was considered as degraded structure.
Study: NCT03513224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eDosette
Description: The eDosette is an internet-enabled, medication administration monitoring unit that has been previously tested for feasibility in older adults. The eDosette was designed to be compatible with different types of weekly medication blister packs and dosettes, and monitors medication-taking behaviour in a patient's home. The eDosette securely transmits this information to a secure server where the information is converted to individual medication administration records. Patients can also use the eDosette to notify their primary care team of potential medication side effects.
Study: NCT04121507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy before allogeneic stem cell transplantation (alloSCT)
Description: High-dose therapy (HDT) prior to alloSCT will consist of FTC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow histology
Description: Bone marrow histology at staging and restaging is only mandatory if the bone marrow was initially involved

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: clinical and laboratory parameters
Description: During staging and restaging examinations, all clinical and laboratory parameters relevant for therapy.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET-CT or CT
Description: Metabolic CR in a PET-CT scan after the last cycle of therapy prior to planned SCT. Consists preferably of a PET-CT or a CT scan according to local practice and other appropriate diagnostic procedures with respect to the sites of primary involvement.
Study: NCT02583048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Four 100 mg tablets (400 mg) orally once a day for 2 weeks, followed by two 100 mg tablets (200 mg) orally three times a week for 22 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Four 100 mg tablets (400 mg) orally once a day for 2 weeks, followed by two 100 mg tablets (200 mg) orally three times a week for 22 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: Two 50 mg tablets (100 mg) orally with food twice a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: Two 50 mg tablets (100 mg) orally with food twice a day for 24 weeks.
Study: NCT01806727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self Management (DSM)
Description: Changing diet, physical activity, self monitoring, and medication related behaviors to improve diabetes control
Study: NCT00768937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: All patients will receive Sorafenib (800 mg/day) p.o. beginning two weeks before the first TACE and every day thereafter until patient death or premature withdrawal from study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolisation (TACE)
Description: TACE will be carried out with doxorubicin (75 - 50 - 25 mg/m2, depending on serum bilirubin levels ≤ 1.5, 1.5 - 3, 3 - 5 mg/dL) : lipiodol (1:1) in a total volume of 20 mL; after administration of doxorubicin:lipiodol, additional embolisation will be carried out with bead block-endospheres. TACE will be repeated every 4 weeks for 3 cycles; additional cycles will be offered if clinically indicated (but no PEI or RF-ablation should be carried out after inclusion into the study)
Study: NCT00894127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyPath
Description: CyPath diagnostic assay for the early detection of lung cancer using sputum
Study: NCT03176875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALICALM (75% of daily caloric requirements)
Description: PEN group will receive 75% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) and 25% of daily dietary needs (1 meal per day) from an antiinflammatory diet for CD (AID-CD) for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ALICALM (100% of daily caloric requirements)
Description: EEN group will receive 100% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) for 6 weeks.
Study: NCT02240173

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jobelyn
Description: Jobelyn is a dietary supplement made from Sorghum bicolor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Conventional drug normally used for psychotic problems
Study: NCT01571297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RM-131
Description: Double blind RM-131 will be studied with various doses and regimens from 10 to 100 μg for 35 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given subcutaneously for 35 days
Study: NCT03645681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InnAVasc arteriovenous graft surgical implant
Description: An InnAVasc AVG will be surgically implanted into the upper arm or forearm of enrolled participants
Study: NCT02193425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18FDG
Description: 18F-Fluorodeoxyglucose (FDG)-PET session to assess the association between functional connectivity (FC) and glucose metabolism in the human brain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Two MRI/MRS sessions to evaluate test-retest reliability of functional connectivity (FC) at rest as well as during task performance.
Study: NCT03733340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem
Description: Imipenem: A wide-spectre antibiotic from the carbapenem group Other name: Imipenem-cilastatin